Abstract:The 2019-2020 winter was marked by the emergence of a new coronavirus (SARS-CoV-2) related disease (COVID-19), which started in Wuhan, China. Its high human-to-human transmission ability led to a worldwide spread within few weeks and has caused substantial human loss. Mechanical antiviral control approach, drug repositioning, and use of COVID-19 convalescent plasmas (CPs) were the first line strategies utilized to mitigate the viral spread, yet insufficient. The urgent need to contain this deadly pandemic has led searchers and pharmaceutical companies to develop vaccines. However, not all vaccines manufactured are safe. Besides, an alternative and effective treatment option for such an infectious disease would include pure anti-viral neutralizing monoclonal antibodies (NmAbs), which can block the virus at specific molecular targets from entering cells by inhibiting virus-cell structural complex formation, with more safety and efficiency than the CP. Indeed, there is a lot of molecular evidence about the protector effect and the use of molecular feature-based NmAbs as promising therapeutics to contain COVID-19. Thus, from the scientific publication database screening, we here retrieved antibody-related papers and summarized the repertory of characterized NmAbs against SARS-CoV-2, their molecular neutralization mechanisms, and their immunotherapeutic pros and cons. About 500 anti-SARS-CoV-2 NmAbs, characterized through competitive binding assays and neutralization efficacy, were reported at the writing time (January 2021). All NmAbs bind respectively to SARS-CoV-2 S and exhibit high molecular neutralizing effects against wild-type and/or pseudotyped virus. Overall, we defined six NmAb groups blocking SARS-CoV-2 through different molecular neutralization mechanisms, from which five potential neutralization sites on SARS-CoV-2 S protein are described. Therefore, more efforts are needed to develop NmAbs-based cocktails to mitigate COVID-19.

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Potently neutralizing and protective human antibodies against SARS-CoV-2

Bispecific Antibodies Targeting Distinct Regions of the Spike Protein Potently Neutralize SARS-CoV-2 Variants of Concern

Ultrapotent Bispecific Antibodies Neutralize Emerging SARS-CoV-2 Variants

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies As Promising Therapeutics Against SARS-CoV-2 Infection

Monospecific and Bispecific Monoclonal SARS-CoV-2 Neutralizing Antibodies That Maintain Potency Against B.1.617

A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction

Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variants

Human neutralizing antibodies elicited by SARS-CoV-2 infection

A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody